MLH1 and neoplasm: EC, the second most common neoplasia in females with LS after CRC, is associated with a lifetime risk of 50%, representing 2% of all ECs; the most frequent variant is MSH2 (cumulative incidence of 48.9% by the age of 75) followed by MSH6, respective of MLH1 mutations [5,8].